Home > Riviste > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Fascicoli precedenti > Gazzetta Medica Italiana Archivio per le Scienze Mediche 2018 April;177(4) > Gazzetta Medica Italiana Archivio per le Scienze Mediche 2018 April;177(4):158-64

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Gazzetta Medica Italiana Archivio per le Scienze Mediche 2018 April;177(4):158-64

DOI: 10.23736/S0393-3660.17.03508-2

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Genetic polymorphism of CYP2D6*41 in different ethnicities of Iranian population

Zohre POURKARAMI 1, 2, M. Hosein SANGTARASH 2, Narges JAFARZADEH 1, Zohre POURSINA 3, Azra IZANLOO 1, Masoud HOUSHMAND 4

1 Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran; 2 Department of Biology, Faculty of Basic Sciences, University of Sistan and Balouchestan, Zahedan, Iran; 3 Department of Biology, Faculty of Basic Sciences, Islamic Azad university East Tehran Branch, Tehran, Iran; 4 Department of Medical Genetics, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran


PDF


BACKGROUND: We investigated the frequency, prevalence and distribution of CYP2D6*41 polymorphism among different ethnicities of Iranian population.
METHODS: Genotyping was performed using PCR-RFLP method on genomic DNA of blood samples from 300 healthy individuals. Then, DNA sequencing technique was applied on some random samples to confirm the results.
RESULTS: Allele frequencies were 64% and 36% for CYP2D6*41[2988G] and CYP2D6*41[2988A]. The most frequency of CYP2D6*41[2988A] allele in ethnicities was owned by Lur ethnicity (42%) and in terms of geographical distribution, the highest prevalence was seen in the southern areas of the country.
CONCLUSIONS: According to this data, lower drug dose should be considered for people who show this polymorphism rather than normal individuals.


KEY WORDS: Pharmacokinetics - Polymorphism, genetic - Cytochrome P-450 enzyme system

inizio pagina